Conference Proceedings and videos for the 2020 Global Conference on Regulatory Science are now up!
READ THE REPORT NOW
Improving the Process of Therapeutic Development
Harvard, MIT, and the FDA have partnered to create a center focused on regulatory science, bringing together a range of scientific disciplines that are applied to assess the quality, safety and efficacy of medicinal products and inform regulatory decision-making throughout the lifecycle of a medicine. Working across academia, industry, and government institutions, the Center promotes regulatory science through research and education programs, uniting stakeholders under a common mission: promoting optimal patient health outcomes through biomedical innovation and the availability of safe and effective diagnostics and treatments.
Featured Publications
The Regulatory Science Fellowship Program
Our fellowship program is affiliated with the FDA and focuses on training the next generation of regulatory science researchers. Learn more about the research our fellows are conducting or explore opportunities and how to get involved in our program.
News, Events, & Updates
RegSci Forum: Benefit-Risk Analysis of Regulatory Decision-Making
GK Raju | May 11, 2021 12-1pm ET
Virtual Webconference
Twitter @Harvardmit_CRS
Wonderful post-doc (including post-JD) opportunity in FDA regulation with @PORTAL_Research https://hmcrs.org/wp-content/uploads/2021/06/HMRS-Post-Dotoral-Position-Sarpatwari-Mentor-060121-Edited.pdf
ICYMI, terrific opportunity for postdoctoral training with @AmeetSarpatwari and group at @PORTAL_Research. This is a high impact group.
https://hmcrs.org/wp-content/uploads/2021/06/HMRS-Post-Dotoral-Position-Sarpatwari-Mentor-060121-Edited.pdf
I talked to @Health_Affairs Editor-in-Chief Alan Weil for this #podcast episode about how #biosimilars are affecting drug markets 💊💉🎙️📲
https://www.healthaffairs.org/do/10.1377/hp20210607.968777/full/
In a new paper featured in our June 2021 issue, Ariel Dora Stern of @HarvardHBS + coauthors investigated biosimilars on the market & found that lower #biosimilar product prices help offset increases in average annual reference-product prices. #DrugPricing https://bit.ly/3vcIew1
Our latest #4CE consortium study via @JAMANetwork demonstrating use of large-scale informatics approaches to support multi-national study of #COVID19 in children: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780925
@HarvardDBMI @Bos_CHIP @avillach